# Vesalius Longevity Labs Commences Trading Today on the Canadian Securities Exchange Under the Symbol "VLAB"

- Link: https://www.thailand-business-news.com/pr-news/vesalius-longevity-labs-commences-trading-today-on-the-canadian-securities-exchange-under-the-symbol-vlab
- Published: 2026-11-12T20:45:00+07:00
- Author: Media OutReach

Vancouver, British Columbia and Scottsdale, Arizona – [Newsfile Corp.](https://www.newsfilecorp.com/)–
November 12, 2026 – [**Vesalius Longevity Labs Inc.**](https://api.newsfilecorp.com/redirect/oPZm3caxQQ)**(
CSE: VLAB) (“Vesalius” **or the** “Company”) **is pleased to announce that it will
commence trading on the Canadian Securities Exchange (“**CSE**“) under the symbol“**
VLAB**” today, November 12, 2026.

 _“Today marks an important milestone for Vesalius Labs, and I want to sincerely
thank our Board of Directors, our entire team, and our shareholders and stakeholders
for their support and guidance throughout our journey so far,”_ said **Dr.** **Pradeep
Albert, MD, CEO of Vesalius Labs**. _“We believe the future is longevity and wellness.
As one of the first publicly traded companies in the sector, Vesalius is well positioned
to become a leading global brand, backed by science and quality. Peptides are one
of the fastest-moving areas in longevity, and we are building the whole path from
lab to consumer. That includes Made-in-the-USA peptide APIs under our Peptual® brand,
a doctor-led model that connects licensed providers with patients, and AI-powered
tools that make care more personalized. Commencing trading on the CSE gives us a
strong platform to help accelerate that vision, and we look forward to an exciting
road ahead.”_

 Additional information on the Company and the business of Vesalius can be found
in the Company’s Listing Statement dated November 9, 2026 as filed on SEDAR+ at 
[www.sedarplus.ca](https://api.newsfilecorp.com/redirect/OAeWmIRwe1).

 **About Vesalius** 
 Vesalius Longevity Labs (CSE: VLAB), is a longevity science
and regenerative health platform focused on being the trusted seed-to-brand partner
across the consumer journey for peptide therapeutics, biologics and preventative
healthcare. Vesalius operates a scalable B2Doctor2Consumer ecosystem designed to
support healthcare providers and telehealth infrastructure. Vesalius will manufacture
under its Peptual® brand “Made-in-the-USA” peptide APIs (active pharmaceutical ingredients)
for domestic and international compounding supply chains. Vesalius’s expanding ecosystem
includes regenerative medicine, multi-faceted compounding pharmacy initiatives, 
biologics partnerships and advanced AI-powered technologies designed to support 
the future of personalized health and wellness.

 Investors interested in learning more about Vesalius Longevity Labs are encouraged
to contact the Company at: [https://www.vesaliuslabs.com/](https://api.newsfilecorp.com/redirect/Pq83kib4eP)

 For further information, please refer to the Company’s disclosure record on SEDAR
+ at [www.sedarplus.ca](https://api.newsfilecorp.com/redirect/wErR5saGRm).

 On Behalf of the Company 
 “Pradeep Albert”  _Chief Executive Officer_

 **Contact:** 
 Julia Becker  _Vice President, Capital Markets_  T: +1 (604) 785-
0850  E: [jbecker@vesaliuslabs.com](https://www.thailand-business-news.com/pr-news/jbecker@vesaliuslabs.com)

 _The CSE has neither approved nor disapproved the contents of this press release._

The issuer is solely responsible for the content of this announcement.

![](//track.media-outreach.com/index.php/WebView/501104/36955)

**Source** : [Vesalius Longevity Labs Commences Trading Today on the Canadian Securities Exchange Under the Symbol "VLAB"](https://www.media-outreach.com/news/united-states/2026/11/12/501104/?rand=186006)

---

  |  This article was produced by Media OutReach, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not reflect the opinions of Thailand Business News. |

---

![Media OutReach Newswire](https://r2.thailand-business-news.com/wp-content/uploads/
2026/10/media-outreach-newswire-2025.svg)
